ClinVar Miner

Submissions for variant NM_000235.4(LIPA):c.662A>G (p.Asp221Gly)

gnomAD frequency: 0.00014  dbSNP: rs145163592
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001450075 SCV000816603 likely benign Wolman disease 2024-01-28 criteria provided, single submitter clinical testing
Eurofins Ntd Llc (ga) RCV000730763 SCV000858526 uncertain significance not provided 2017-12-05 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV001080631 SCV001265190 uncertain significance Lysosomal acid lipase deficiency 2018-01-13 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Ambry Genetics RCV002360730 SCV002664515 uncertain significance Cardiovascular phenotype 2022-04-22 criteria provided, single submitter clinical testing The p.D221G variant (also known as c.662A>G), located in coding exon 5 of the LIPA gene, results from an A to G substitution at nucleotide position 662. The aspartic acid at codon 221 is replaced by glycine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Preventiongenetics, part of Exact Sciences RCV003424280 SCV004117001 uncertain significance LIPA-related condition 2023-05-31 criteria provided, single submitter clinical testing The LIPA c.662A>G variant is predicted to result in the amino acid substitution p.Asp221Gly. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.43% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/variant/10-90984862-T-C). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.